Open AccessLiver transplantation for primary biliary cholangitis (review)
Author(s) -
I. M. Iljinsky,
О. М. Цирульникова
Publication year - 2022
Publication title -
vestnik transplantologii i iskusstvennyh organov
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 5
eISSN - 2412-6160
pISSN - 1995-1191
DOI - 10.15825/1995-1191-2022-1-15-22
Subject(s) - obeticholic acid , medicine , primary biliary cirrhosis , liver transplantation , ursodeoxycholic acid , gastroenterology , liver disease , biliary cirrhosis , transplantation , disease , cirrhosis , autoimmune disease , receptor , agonist
Primary biliary cholangitis (PBC) is an autoimmune liver disease resulting from the destruction and inflammation of intrahepatic bile ducts. This end-stage disease was once the most common cause of liver transplantation. The use of ursodeoxycholic and obeticholic acids as a first-line and second-line treatment, respectively, slows down the disease. However, treatment is not effective in about 40% of PBC patients, and the disease may progress to cirrhosis and end-stage liver disease. These patients undergo liver transplantation to save their lives. After surgery, recurrent PBC can develop in a milder form and rarely requires liver retransplantation.